Plasma glucose (PG) is filtered by the glomerulus and reabsorbed in the proximal tubule via the sodium-dependent glucose transporters, SGLT2 and SGLT1 ([@B1]). The relationship between PG and renal glucose filtration, reabsorption, and excretion is generally described as a threshold-type relationship ([@B2]) and the renal threshold for glucose excretion (RT~G~) is often reported as 180--200 mg/dL (10--11 mM) in healthy subjects ([@B2]--[@B4]).

SGLT2 inhibitors are emerging as potential antidiabetic therapies ([@B5], [@B6]). In diabetic rats, the SGLT2 inhibitor canagliflozin lowered mean RT~G~ from 415 to 94 mg/dL (23--5 mM) ([@B7]).

The availability of a simple method to estimate RT~G~ would facilitate investigation of factors regulating renal glucose transport. The gold-standard stepwise hyperglycemic clamp procedure (SHCP) method can only be applied in specialized laboratories. A new method for estimating RT~G~ using measurements obtained under standard clinical trial conditions has been used to characterize the effects of canagliflozin on RT~G~ ([@B8], [@B9]). This study compared RT~G~ values obtained using the new method during a mixed-meal tolerance test (MMTT) with those obtained using SHCP in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus (T2DM).

Materials and Methods
=====================

Subjects
--------

Eligible subjects were men and women aged 18 to 65 years with T2DM, body mass index of 20 to 39.9 kg/m^2^, glycated hemoglobin of 7.0% to 10.0%, on stable metformin dose or no antihyperglycemic medications, with fasting blood glucose (BG) of 144 to 270 mg/dL (8--15 mM). Subjects participated in either part 1 or part 2 (not both).

This study was conducted at 1 center in Germany. The protocol and amendment were approved by an Independent Ethics Committee. All subjects gave written informed consent, in accordance with the Declaration of Helsinki, following institutional guidelines, and in compliance with Good Clinical Practices and regulatory requirements.

Design
------

This was an open-label study in untreated (part 1) or canagliflozin-treated (part 2) subjects. In part 1, subjects entered the clinical research unit on day −1 and 12-hour creatinine clearance (CrCl~12h~) was measured. Following an overnight fast, subjects underwent an MMTT on day 1 and SHCP on day 2. In part 2, canagliflozin 100 mg was given once a day for 8 days. Subjects entered the clinical research unit on day 6 and CrCl~12h~ was measured; MMTT was performed on day 7 (10 min after canagliflozin dosing), and SHCP was performed on day 8 (canagliflozin was dosed after the lowest glycemic target was reached).

Procedures
----------

The MMTT contained approximately 700 kcal (including 100 g carbohydrates) and was given at t = 0 (0800 hours). BG was measured at t = −15, 0, 30, 60, 90, 120, 180, and 240 minutes. Urine was collected over 0 to 2 hours and 2 to 4 hours. SHCP was performed using Biostator (Life Science Instruments, Elkhardt, Indiana) through retrograde catheterization in a hand vein heated to 55°C to measure arterialized venous BG. In part 1, BG targets were 126, 171, 216, 261, and 306 mg/dL (7--17 mM). BG was reduced to 126 mg/dL using iv regular insulin infusion and maintained there for approximately 2 hours. Subsequent clamp steps were achieved using 20% glucose infusion with bolus infusions to reach BG targets quickly; each step was maintained for 2.5 hours. Part 2 used BG targets of 72, 117, 162, 207, and 252 mg/dL (4--14 mM). Urine was collected over the first hour and last 1.5 hours of each step.

Bioanalytical
-------------

Blood and urine glucose were determined by the Biostator; a glucose oxidase-based reference method (Super GL Glucose Analyzer; Hitado GmbH, Möhnesee, Germany) was used for confirmation. GFR was estimated using MDRD formula (estimated glomerular filtration rates \[eGFR\]) ([@B10]) and CrCl~12h~.

Determining RT~G~
-----------------

The relationship between urinary glucose excretion (UGE) and BG was approximated by an idealized threshold relationship: $$\text{rate}\,\text{of}\,\text{UGE}\,\left( {\text{mg}/\min} \right) = \begin{cases}
0 & {\text{if}\,\text{BG} \leq \text{RT}_{\text{G}}} \\
{\text{GFR}\,\left( {\text{dL}/\min} \right) \times \left( {\text{BG}\,\left( {\text{mg}/\text{dL}} \right) - \text{RT}_{\text{G}}\left( {\text{mg}/\text{dL}} \right)} \right)} & {\text{if}\,\text{BG} > \text{RT}_{\text{G}}} \\
\end{cases}$$ as used previously ([@B11], [@B12]). For SHCP, RT~G:SHCP~ was determined using robust nonlinear regression (*nlinfit* in Matlab \[[@B13]\]) with [equation 1](#FD1){ref-type="disp-formula"} and measured UGE and BG during the last 1.5 hours of the 5 clamp steps. Best-fit values of RT~G~ and GFR were obtained for all subjects except for 1 subject in part 1, who had too little UGE during several steps for both RT~G~ and GFR to be estimated, and for 2 subjects in part 2 for whom no physiologically reasonable RT~G~ value could be determined. For the subject in part 1 with low UGE, GFR was set to CrCl~12h~ and regression was used to determine RT~G~.

For the MMTT, RT~G:MMTT~ was calculated from [equation 1](#FD1){ref-type="disp-formula"} using measured BG, UGE, and eGFR (CrCl~12h~ was used for comparison), as previously described ([@B8], [@B9]). Because the true BG vs UGE relationship is not a perfect threshold and even normoglycemic subjects (where BG ≪ RT~G~) have small amounts of UGE, RT~G:MMTT~ was only estimated for subjects with UGE \> 600 mg. This value was chosen based on previous studies in nondiabetic subjects where 98% of subjects had 24-hour UGE \< 600 mg ([@B9]) and because the 3 subjects in part 1 whose BG remained below their RT~G:SHCP~ values during the entire MMTT had UGE of 0 to 589 mg, whereas all other subjects had UGE \> 1 g. In part 2, RT~G:MMTT~ was not determined for 1 subject due to incomplete urine collection.

Statistical analyses
--------------------

Values reported are mean ± SD. Comparisons used all subjects with RT~G~ values for both methods (n = 11 in each part) using a mixed-effects ANOVA model. Least-squares geometric means and 90% confidence intervals (CIs) of log-transformed RT~G~ values were calculated. The concordance correlation coefficient was calculated using Lin\'s approach in SAS ([@B14]). Similarity was assessed using the following 2 prespecified criteria: 1) estimated concordance correlation coefficient ≥ 0.7, and 2) 90% CI for the geometric mean ratio (GMR) of RT~G:MMTT~/RT~G:SHCP~ within 0.8 to 1.25.

Results
=======

Subjects
--------

Twenty-eight subjects were enrolled and completed the study. Baseline characteristics are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Demographic and Baseline Characteristics^[a](#TF1-1){ref-type="table-fn"}^

  Parameter^[b](#TF1-2){ref-type="table-fn"}^                      Part 1: No Treatment (n = 14)   Part 2: Canagliflozin 100 mg (n = 14)
  ---------------------------------------------------------------- ------------------------------- ---------------------------------------
  Age, y                                                           57 (45--63)                     58 (38--66)
  Gender, n                                                                                        
      Male                                                         10                              10
      Female                                                       4                               4
  Race, n                                                                                          
      White                                                        14                              14
  BMI, kg/m^2^                                                     31 (24--36)                     29 (20--36)
  eGFR,^[c](#TF1-3){ref-type="table-fn"}^ mL/min/1.73 m^2^         88 (71--121)                    89 (74--126)
  CrCl~12h~,^[d](#TF1-4){ref-type="table-fn"}^ mL/min/1.73 m^2^    121 (22)                        116 (27)
  Glycated hemoglobin, %                                           8.4 (7.1--9.4)                  7.8 (7.0--9.6)
  Fasting serum glucose, mg/dL                                     203.6 (144.1--252.3)            198.2 (144.1--252.3)
  Fasting serum glucose, mM                                        11.3 (8--14)                    11.0 (8--14)
  Subjects taking metformin,^[e](#TF1-5){ref-type="table-fn"}^ n   14                              12

Abbreviations: BMI, body mass index; CrCl~12h~, measured 12-hour creatinine clearance; MDRD, modification of diet in renal disease.

All values except for CrCl~12h~ were measured at the screening visit.

Values shown are median (range) except for gender, race, CrCl~12h~, and subjects taking metformin.

Calculated using the MDRD formula ([@B10]).

Mean (SD) values measured on day −1 in part 1 and day 6 in part 2.

Subjects in this study were allowed to be on either a stable dose of metformin or no antihyperglycemic medications.

BG and UGE during MMTT and SHCP
-------------------------------

[Figure 1](#F1){ref-type="fig"} depicts BG and UGE during the MMTT and SHCP in untreated subjects ([Figure 1](#F1){ref-type="fig"}, A--D) and canagliflozin-treated subjects ([Figure 1](#F1){ref-type="fig"}, E--H). UGE rates during each clamp step and in the MMTT were higher in canagliflozin-treated subjects than in untreated subjects.

![(A--H) BG concentrations and UGE during the SHCP and MMTT procedures in part 1 (untreated subjects; A--D) and part 2 (canagliflozin-treated subjects; E--H). Results shown are mean ± SD. UGE rates shown are the average rates measured during the last 1.5 hours of each hyperglycemic clamp step (B and F) or during the time interval shown from the MMTT (D and H). (I and J) Determination of RT~G~ from the SHCP. (I) Data from an individual subject. Measured UGE rate and mean BG concentration in each of the 5 clamp steps (dots) and the best fit obtained to [equation 1](#FD1){ref-type="disp-formula"} (line) are shown; the fit value of RT~G~ = 203.6 mg/dL (11.3 mM) was obtained for this subject. (J) Data from all 14 subjects in part 1. Each dot represents data from an individual subject during 1 of the 5 clamp steps, where the UGE rate is shown on the y-axis and the difference between the BG concentration in the clamp step and the subject\'s RT~G~ is shown on the x-axis. As in [equation 1](#FD1){ref-type="disp-formula"}, subjects have virtually no UGE when BG \< RT~G~ and the rate of UGE increases in proportion to BG-RT~G~ when BG \> RT~G~. (K) BG vs UGE relationship in untreated and canagliflozin-treated subjects. Values shown are mean ± SD. (L) Relationship between RT~G~ values determined by the MMTT and SHCP methods. Individual subject values (n = 11 each in part 1 and part 2) are shown as filled squares (part 1) or open circles (part 2); the dotted line represents the line of identity (exact agreement between the 2 methods).](zeg9991398640001){#F1}

BG vs UGE relationship during SHCP
----------------------------------

In untreated subjects, the BG vs UGE relationship was well-described by the idealized threshold model ([equation 1](#FD1){ref-type="disp-formula"}), as shown for a representative individual subject ([Figure 1](#F1){ref-type="fig"}I) and for all untreated subjects ([Figure 1](#F1){ref-type="fig"}J), and RT~G:SHCP~ = 216.2 ± 23.4 mg/dL (12.0 ± 1.3 mM) in untreated subjects. The UGE vs BG relationship was left-shifted in canagliflozin-treated subjects, with RT~G:SHCP~ = 48.6 ± 19.8 mg/dL (2.7 ± 1.1 mM) in canagliflozin-treated subjects ([Figure 1](#F1){ref-type="fig"}K).

Comparison of the MMTT and SHCP methods
---------------------------------------

RT~G~ values obtained by the 2 methods were highly correlated ([Figure 1](#F1){ref-type="fig"}L), with an overall concordance correlation coefficient of 0.94, above the prespecified similarity criterion of 0.7. There was also good agreement when assessing the GMRs for RT~G:MMTT~/RT~G:SHCP~: GMRs (90% CIs) of 0.93 (0.89--0.96) in part 1 and 1.03 (0.78--1.37) in part 2. When considering the concordance correlation coefficients for part 1 and part 2 separately, values of 0.71 and 0.49 were obtained, respectively. Potential reasons for some within-subject differences in RT~G:MMTT~ and RT~G:SHCP~ values observed within each part are described in the *Discussion*.

The comparisons described above are for analyses performed with eGFR used to estimate GFR during the RT~G:MMTT~ calculations. Good agreement between MMTT and SHCP-derived RT~G~ values was also obtained when CrCl~12h~ was used to determine RT~G:MMTT~ in untreated subjects (GMR \[90% CI\] = 0.97 \[0.94--1.01\] for part 1), but the RT~G:MMTT~ values obtained using CrCl~12h~ overestimated the clamp-derived values in canagliflozin-treated subjects (GMR \[90% CI\] = 1.86 \[1.40--2.47\] for part 2).

Safety and tolerability
-----------------------

Study procedures and treatments were well-tolerated. A higher incidence of adverse events was reported for canagliflozin-treated (n = 11) vs untreated (n = 2) subjects. This was primarily due to increased osmotic diuresis-related events (ie, pollakiuria, polyuria; n = 6 for canagliflozin vs 0 for untreated); these were generally mild and did not cause any discontinuations. No clinically significant clinical chemistry parameter changes were observed.

Discussion
==========

This study validated a recently developed method for estimating RT~G~ from measurements commonly collected in clinical trials ([@B8], [@B9]). Although the method for calculating RT~G~ using dynamic plasma and urine data is novel, the formulas used are straightforward generalizations of the established method for phosphate excretion ([@B15], [@B16]) and account for dynamic BG changes and possible times when BG \< RT~G~. This new method is much more generally applicable than the SHCP due to the far simpler experimental procedure. Strong agreement between RT~G~ values obtained by the 2 methods was observed, with an overall concordance correlation coefficient of 0.94 and GMRs of 0.93 in untreated subjects and 1.03 in canagliflozin-treated subjects.

Although the overall concordance correlation coefficient of 0.94 suggests strong overall agreement between the methods, the concordance was not quite as strong when considering each study part separately, particularly for the treated subjects. In untreated subjects, the between-methods difference in RT~G~ was \<27 mg/dL (1.5 mM) (within expected precision for 45 mg/dL \[2.5 mM\] clamp steps) for all except 1 subject whose RT~G:SHCP~ value was not consistent with the data observed during the MMTT (the subject had \>3 g of UGE during the MMTT despite BG remaining below RT~G:SHCP~ during the entire MMTT period, suggesting the RT~G:SHCP~ value was inconsistent with MMTT observations). In canagliflozin-treated subjects, some unexpected within-subject differences in canagliflozin pharmacokinetics between the MMTT and SHCP (eg, slower absorption and delayed T~max~) likely contributed to within-subject RT~G~ differences. Because the within-subject differences in RT~G~ values were generally small and some of the largest discrepancies were attributable to pharmacokinetic differences or to a clamp-derived RT~G~ value that was inconsistent with the MMTT data, the reduced concordance observed when considering the groups separately would not limit the utility of the new method.

RT~G~ values in canagliflozin-treated subjects in this study are modestly lower than previously reported in subjects with T2DM ([@B8]), due in part to using BG concentrations here and plasma concentrations in Ref. [@B8] (BG concentrations are ∼15% lower than plasma concentrations \[[@B17]\]).

Although the new method offers a practical method for estimating RT~G~, there are some limitations. The primary limitation is that subjects must have BG \> RT~G~ to have sufficient UGE to determine RT~G~; therefore, the method is not applicable in untreated normoglycemic or mildly hyperglycemic subjects with only trace amounts of UGE during an MMTT. In these cases, all that can be said is that RT~G~ is above the highest BG concentration measured. Consistent with this, for the 3 untreated subjects in this study with UGE \< 600 mg during the MMTT, peak BG during the MMTT remained below their RT~G:SHCP~ values. Another limitation is that the method assumes the BG vs UGE relationship can be approximated by a perfect threshold without splay and no information about the splay region is identified; however, very little splay was observed in the UGE vs BG relationship during the SHCP ([Figure 1](#F1){ref-type="fig"}, I and J). Additionally, because only estimated GFR values are used, precise estimates of renal glucose reabsorption rates are not obtained from the new method.

In summary, we have developed a simple, straightforward method based on easily collected clinical data for determining RT~G~ in untreated and canagliflozin-treated subjects with T2DM and have demonstrated that RT~G~ values determined using this new method agree well with those derived using the more complicated SHCP method.

Abbreviations: BGblood glucoseCIconfidence intervalCrCl~12h~measured 12-hour creatinine clearanceeGFRestimated glomerular filtration ratesGMRgeometric mean ratioMMTTmixed-meal tolerance testPGplasma glucoseRT~G~renal threshold for glucose excretionSGLTsodium-dependent glucose transporterSHCPstepwise hyperglycemic clamp procedureT2DMtype 2 diabetes mellitusUGEurinary glucose excretion.
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